ETF Managers Group LLC Raises Holdings in Emergent BioSolutions Inc. (NYSE:EBS)

Posted by Defense World Staff on Jul 2nd, 2023

ETF Managers Group LLC lifted its holdings in shares of Emergent BioSolutions Inc. (NYSE:EBS – Free Report) by 33.8% during the first quarter, according to its most recent disclosure with the SEC. The fund owned 16,647 shares of the biopharmaceutical company’s stock after acquiring an additional 4,209 shares during the period. ETF Managers Group LLC’s holdings in Emergent BioSolutions were worth $172,000 at the end of the most recent quarter.

A number of other large investors have also recently bought and sold shares of the company. Covestor Ltd boosted its position in Emergent BioSolutions by 43.8% in the first quarter. Covestor Ltd now owns 1,612 shares of the biopharmaceutical company’s stock valued at $66,000 after buying an additional 491 shares during the last quarter. Baird Financial Group Inc. boosted its position in Emergent BioSolutions by 9.1% in the first quarter. Baird Financial Group Inc. now owns 7,313 shares of the biopharmaceutical company’s stock valued at $300,000 after buying an additional 607 shares during the last quarter. Centaurus Financial Inc. boosted its position in Emergent BioSolutions by 19.6% in the first quarter. Centaurus Financial Inc. now owns 3,796 shares of the biopharmaceutical company’s stock valued at $156,000 after buying an additional 621 shares during the last quarter. Guggenheim Capital LLC boosted its position in Emergent BioSolutions by 0.8% in the first quarter. Guggenheim Capital LLC now owns 85,792 shares of the biopharmaceutical company’s stock valued at $3,522,000 after buying an additional 680 shares during the last quarter. Finally, Ancora Advisors LLC purchased a new stake in Emergent BioSolutions in the first quarter valued at approximately $66,000. Hedge funds and other institutional investors own 87.64% of the company’s stock.

Emergent BioSolutions Trading Down 3.5 %

Shares of NYSE:EBS opened at $7.35 on Friday. The company has a current ratio of 1.00, a quick ratio of 0.70 and a debt-to-equity ratio of 0.37. The company has a market capitalization of $370.81 million, a PE ratio of -0.91 and a beta of 0.93. The business has a 50 day moving average of $8.69 and a two-hundred day moving average of $10.77. Emergent BioSolutions Inc. has a 12-month low of $7.33 and a 12-month high of $36.14.

Emergent BioSolutions (NYSE:EBS – Free Report) last announced its earnings results on Tuesday, May 9th. The biopharmaceutical company reported ($3.17) earnings per share for the quarter, missing the consensus estimate of ($1.67) by ($1.50). The business had revenue of $165.10 million for the quarter, compared to analyst estimates of $142.85 million. Emergent BioSolutions had a negative return on equity of 20.18% and a negative net margin of 41.20%. The company’s quarterly revenue was down 46.3% compared to the same quarter last year. During the same period in the previous year, the company earned $0.18 earnings per share. As a group, analysts forecast that Emergent BioSolutions Inc. will post -1.49 EPS for the current year.

Analysts Set New Price Targets

EBS has been the topic of a number of recent research reports. StockNews.com initiated coverage on Emergent BioSolutions in a research report on Thursday, May 18th. They issued a “sell” rating on the stock. Benchmark raised Emergent BioSolutions from a “hold” rating to a “buy” rating and set a $22.00 price target for the company in a report on Monday, April 10th. Finally, JPMorgan Chase & Co. reissued an “underweight” rating and issued a $9.00 price target (down from $23.00) on shares of Emergent BioSolutions in a report on Friday, March 17th. Two analysts have rated the stock with a sell rating, two have given a hold rating and two have assigned a buy rating to the company. According to data from MarketBeat, Emergent BioSolutions has a consensus rating of “Hold” and a consensus target price of $28.00.

Emergent BioSolutions Company Profile

(Free Report)

Emergent BioSolutions Inc, a life sciences company, focuses on the provision of preparedness and response solutions that address accidental, deliberate, and naturally occurring public health threats (PHTs) in the United States. Its products address PHTs, which include chemical, biological, radiological, nuclear, and explosives; emerging infectious diseases; travel health; public health crises; and acute, emergency, and community care.

ETF Managers Group LLC Raises Holdings in Emergent BioSolutions Inc. (NYSE:EBS)

Emergent BioSolutions Trading Down 3.5 %

Analysts Set New Price Targets

Emergent BioSolutions Company Profile

Further Reading

You might be interested in: